{"id":237035,"date":"2021-04-02T14:54:44","date_gmt":"2021-04-02T18:54:44","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=237035"},"modified":"2021-04-05T10:16:29","modified_gmt":"2021-04-05T14:16:29","slug":"cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/","title":{"rendered":"Cuba: First stage of phase III trial with Soberana 02 concludes"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">The first stage of phase III clinical trial of the Cuban Soberana 02 <\/span><a href=\"https:\/\/oncubanews.com\/en\/coronavirus\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">COVID-19<\/span><\/a> <a href=\"https:\/\/oncubanews.com\/en\/tag\/cuban-vaccine-against-covid-19\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">vaccine candidate<\/span><\/a><span style=\"font-weight: 400;\"> concluded this Wednesday in <\/span><a href=\"https:\/\/oncubanews.com\/en\/tag\/havana\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Havana<\/span><\/a><span style=\"font-weight: 400;\">, after the administration of the first dose to the last of the 44,010 volunteers participating in the study.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response,\u201d according to the <\/span><a href=\"http:\/\/www.acn.cu\/salud\/78249-soberana-02-alentadores-resultados-tras-primera-etapa-de-fase-iii-de-ensayo-clinico\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Agencia Cubana de Noticias<\/span><\/a><span style=\"font-weight: 400;\"> news agency.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">During an appearance on Cuban television, Dr. Toledo explained that the first stage of this phase was completed within 18 days and that it involved 31 clinical sites and 48 vaccination centers located in eight municipalities of the Cuban capital, where the vaccine candidate developed by the state Finlay Institute was inoculated.<\/span><\/p>\n<blockquote class=\"twitter-tweet\" data-width=\"500\" data-dnt=\"true\">\n<p lang=\"es\" dir=\"ltr\">El paciente 44 mil 10 del ensayo cl\u00ednico Fase III de <a href=\"https:\/\/twitter.com\/hashtag\/Soberana02?src=hash&amp;ref_src=twsrc%5Etfw\">#Soberana02<\/a> tiene 57 a\u00f1os, su origen es de Granma y su nombre Fidel. <a href=\"https:\/\/twitter.com\/BalbinYury?ref_src=twsrc%5Etfw\">@BalbinYury<\/a> sella su pecho con <a href=\"https:\/\/twitter.com\/hashtag\/AlgoM%C3%A1sQueUnaVacuna?src=hash&amp;ref_src=twsrc%5Etfw\">#AlgoM\u00e1sQueUnaVacuna<\/a>, lo hace con la <a href=\"https:\/\/twitter.com\/hashtag\/FuerzaDeUnPa%C3%ADs?src=hash&amp;ref_src=twsrc%5Etfw\">#FuerzaDeUnPa\u00eds<\/a>. <br \/>Esto sucede hoy en el Policl\u00ednico Ra\u00fal G\u00f3mez Garc\u00eda de 10 de Octubre. <a href=\"https:\/\/t.co\/r7k6UyzURq\">pic.twitter.com\/r7k6UyzURq<\/a><\/p>\n<p>&mdash; Instituto Finlay de Vacunas (@FinlayInstituto) <a href=\"https:\/\/twitter.com\/FinlayInstituto\/status\/1377361888011452416?ref_src=twsrc%5Etfw\">March 31, 2021<\/a><\/p><\/blockquote>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n<p><span style=\"font-weight: 400;\">The specialist reported that COVID-19 cases have been reported among the volunteers, although \u201cmost have suffered from mild forms of the disease.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400;\">She said that more than 82% of recorded adverse events have been mild, while serious adverse events were associated with antigen-positive hospitalizations.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cAfter the administration of the vaccine, adverse events are always reported, which are expected, such as pain, inflammation at the injection site, general malaise and fever,\u201d said the doctor.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Likewise, she explained that study participants can become infected with the coronavirus, because \u201cfor them to be fully protected it is necessary to complete the vaccination scheme,\u201d in addition to the fact that the vaccine must prevent COVID-19, not infection with the virus.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The study with this vaccine candidate will continue, following the design implemented by its developers, with two vaccination schemes, one of two doses and the other of three doses, which are administered on days zero, 28 and 56 of the test. The specialist explained that the sample of volunteers is divided into three groups, of which one will receive a placebo.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to Toledo, it is a blind test, which is why \u201ceach of the individuals who entered the Soberana 02 trial has an inclusion number and, based on this, is assigned to one of the groups.\u201d Once the vaccination schemes are completed, the codes will be revealed and it will be known who was injected with the vaccine candidate and who with the placebo, explained Toledo.<\/span><\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"Wvw4c6nadh\"><p><a href=\"https:\/\/oncubanews.com\/en\/coronavirus\/more-than-100000-cuban-volunteers-receive-first-dose-in-studies-on-covid-19-vaccines\/\">More than 100,000 Cuban volunteers receive first dose in studies on COVID-19 vaccines<\/a><\/p><\/blockquote>\n<p><iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;More than 100,000 Cuban volunteers receive first dose in studies on COVID-19 vaccines&#8221; &#8212; OnCubaNews English\" src=\"https:\/\/oncubanews.com\/en\/coronavirus\/more-than-100000-cuban-volunteers-receive-first-dose-in-studies-on-covid-19-vaccines\/embed\/#?secret=zWV04k5vj6#?secret=Wvw4c6nadh\" data-secret=\"Wvw4c6nadh\" width=\"500\" height=\"282\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n<p><span style=\"font-weight: 400;\">The researcher specified that at the end of the study all the volunteers will benefit from the complete vaccination of the scheme that shows the best result in terms of efficacy.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Thus, if the three-dose schedule (two of Soberana 02 plus one of Soberana Plus) is the best, the subjects who were injected only with the Soberana 02 doses will receive the complete scheme.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Meanwhile, the volunteers who received the placebo will be followed for three months, and then the established vaccination scheme will be administered to them.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cuba has five COVID-19 vaccine candidates in human clinical trials, and in addition to Soberana 02, the candidate Abdala, developed by the Center for Genetic Engineering and Biotechnology (CIGB), is also in the third phase of studies. In addition, with both, controlled interventions are developed in groups selected by the authorities, such as health workers, scientists and athletes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">So far, Cuban specialists evaluate the development of the tests as positive. In the case of clinical trials, these seek to measure the safety, efficacy and immunogenicity of the formulations, while the controlled intervention aims to evaluate the direct and indirect effects of vaccination against SARS-CoV-2, in population cohorts of risk of infection, disease and spread of the epidemic.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cuban authorities recently announced a roadmap that includes the application of the two potential vaccines to hundreds of thousands of people in the next three months, under the figure of population-based intervention studies. Among them is one in Havana that plans to administer one of the two vaccine candidates to 1.7 of the 2.2 million inhabitants of the capital, the current epicenter of the pandemic on the island.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response.\u201d<\/p>\n","protected":false},"author":3134,"featured_media":237037,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33393,13916],"tags":[29532,18518,33386],"ppma_author":[33546],"class_list":["post-237035","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-coronavirus","category-science-in-cuba","tag-coronavirus-in-cuba","tag-cover","tag-cuban-vaccine-against-covid-19"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cuba: First stage of phase III trial with Soberana 02 concludes | OnCubaNews English<\/title>\n<meta name=\"description\" content=\"The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response.\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cuba: First stage of phase III trial with Soberana 02 concludes | OnCubaNews English\" \/>\n<meta property=\"og:description\" content=\"The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response.\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/\" \/>\n<meta property=\"og:site_name\" content=\"OnCubaNews English\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-02T18:54:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-05T14:16:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/04\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"458\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"OnCuba Staff\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"OnCuba Staff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/\"},\"author\":{\"name\":\"OnCuba Staff\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/d7171bf311032ab1f557dd8332e714af\"},\"headline\":\"Cuba: First stage of phase III trial with Soberana 02 concludes\",\"datePublished\":\"2021-04-02T18:54:44+00:00\",\"dateModified\":\"2021-04-05T14:16:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/\"},\"wordCount\":683,\"commentCount\":2,\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg\",\"keywords\":[\"coronavirus in Cuba\",\"cover\",\"Cuban vaccine against COVID-19\"],\"articleSection\":[\"Coronavirus\",\"Science in Cuba\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#respond\"]}],\"copyrightYear\":\"2021\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/\",\"name\":\"Cuba: First stage of phase III trial with Soberana 02 concludes | OnCubaNews English\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg\",\"datePublished\":\"2021-04-02T18:54:44+00:00\",\"dateModified\":\"2021-04-05T14:16:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/d7171bf311032ab1f557dd8332e714af\"},\"description\":\"The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response.\u201d\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg\",\"contentUrl\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg\",\"width\":750,\"height\":458,\"caption\":\"The first stage of the phase III clinical trial with the Cuban Soberana 02 vaccine candidate concluded after administering a dose of the formulation to volunteer 44,010. Photo: @cubadebatecu\\\/Twitter.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/coronavirus\\\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cuba: First stage of phase III trial with Soberana 02 concludes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/\",\"name\":\"OnCubaNews English\",\"description\":\"Revista sobre Cuba\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/#\\\/schema\\\/person\\\/d7171bf311032ab1f557dd8332e714af\",\"name\":\"OnCuba Staff\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g17310096d4dde63ebae0e54fbb19218a\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g\",\"caption\":\"OnCuba Staff\"},\"url\":\"https:\\\/\\\/oncubanews.com\\\/en\\\/author\\\/oncuba-editorial-staff\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cuba: First stage of phase III trial with Soberana 02 concludes | OnCubaNews English","description":"The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response.\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/","og_locale":"en_US","og_type":"article","og_title":"Cuba: First stage of phase III trial with Soberana 02 concludes | OnCubaNews English","og_description":"The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response.\u201d","og_url":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/","og_site_name":"OnCubaNews English","article_published_time":"2021-04-02T18:54:44+00:00","article_modified_time":"2021-04-05T14:16:29+00:00","og_image":[{"width":750,"height":458,"url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/04\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg","type":"image\/jpeg"}],"author":"OnCuba Staff","twitter_card":"summary_large_image","twitter_misc":{"Written by":"OnCuba Staff","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#article","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/"},"author":{"name":"OnCuba Staff","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/d7171bf311032ab1f557dd8332e714af"},"headline":"Cuba: First stage of phase III trial with Soberana 02 concludes","datePublished":"2021-04-02T18:54:44+00:00","dateModified":"2021-04-05T14:16:29+00:00","mainEntityOfPage":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/"},"wordCount":683,"commentCount":2,"image":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/04\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg","keywords":["coronavirus in Cuba","cover","Cuban vaccine against COVID-19"],"articleSection":["Coronavirus","Science in Cuba"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#respond"]}],"copyrightYear":"2021","copyrightHolder":{"@id":"https:\/\/oncubanews.com\/en\/#organization"}},{"@type":"WebPage","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/","url":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/","name":"Cuba: First stage of phase III trial with Soberana 02 concludes | OnCubaNews English","isPartOf":{"@id":"https:\/\/oncubanews.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#primaryimage"},"image":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#primaryimage"},"thumbnailUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/04\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg","datePublished":"2021-04-02T18:54:44+00:00","dateModified":"2021-04-05T14:16:29+00:00","author":{"@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/d7171bf311032ab1f557dd8332e714af"},"description":"The study\u2019s principal researcher, Dr. Mar\u00eda Eugenia Toledo, stated that so far the results of the process are \u201cencouraging in terms of the safety of the product and the immune response.\u201d","breadcrumb":{"@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#primaryimage","url":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/04\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg","contentUrl":"https:\/\/oncubanews.com\/en\/wp-content\/uploads\/2021\/04\/Ensayo-fase-III-Soberana-02-Cuba-750x458-1.jpg","width":750,"height":458,"caption":"The first stage of the phase III clinical trial with the Cuban Soberana 02 vaccine candidate concluded after administering a dose of the formulation to volunteer 44,010. Photo: @cubadebatecu\/Twitter."},{"@type":"BreadcrumbList","@id":"https:\/\/oncubanews.com\/en\/coronavirus\/cuba-first-stage-of-phase-iii-trial-with-soberana-02-concludes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/oncubanews.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cuba: First stage of phase III trial with Soberana 02 concludes"}]},{"@type":"WebSite","@id":"https:\/\/oncubanews.com\/en\/#website","url":"https:\/\/oncubanews.com\/en\/","name":"OnCubaNews English","description":"Revista sobre Cuba","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oncubanews.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oncubanews.com\/en\/#\/schema\/person\/d7171bf311032ab1f557dd8332e714af","name":"OnCuba Staff","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g17310096d4dde63ebae0e54fbb19218a","url":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g","caption":"OnCuba Staff"},"url":"https:\/\/oncubanews.com\/en\/author\/oncuba-editorial-staff\/"}]}},"authors":[{"term_id":33546,"user_id":3134,"is_guest":0,"slug":"oncuba-editorial-staff","display_name":"OnCuba Staff","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/4b4c4d6109baadde898bb1af22ea4a4af5f4417b86a5d1800bf17531bfb128fc?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/237035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/users\/3134"}],"replies":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/comments?post=237035"}],"version-history":[{"count":0,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/posts\/237035\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media\/237037"}],"wp:attachment":[{"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/media?parent=237035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/categories?post=237035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/tags?post=237035"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/oncubanews.com\/en\/wp-json\/wp\/v2\/ppma_author?post=237035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}